Apellis Pharmaceuticals (APLS) Short Interest Ratio & Short Volume $24.27 -0.01 (-0.04%) Closing price 03/28/2025 04:00 PM EasternExtended Trading$24.28 +0.01 (+0.04%) As of 03/28/2025 05:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock Apellis Pharmaceuticals Short Interest DataApellis Pharmaceuticals (APLS) has a short interest of 19.31 million shares, representing 16.66% of the float (the number of shares available for trading by the public). This marks a -7.25% decrease in short interest from the previous month. The short interest ratio (days to cover) is 11.0, indicating that it would take 11.0 days of the average trading volume of 2.05 million shares to cover all short positions.Current Short Interest19,310,000 sharesPrevious Short Interest20,820,000 sharesChange Vs. Previous Month-7.25%Dollar Volume Sold Short$476.18 millionShort Interest Ratio11.0 Days to CoverLast Record DateMarch 15, 2025Outstanding Shares125,516,000 sharesShort Percent of Float16.66%Today's Trading Volume3,800,445 sharesAverage Trading Volume2,050,056 sharesToday's Volume Vs. Average185% Short Selling Apellis Pharmaceuticals? Sign up to receive the latest short interest report for Apellis Pharmaceuticals and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartAPLS Short Interest Over TimeAPLS Days to Cover Over TimeAPLS Percentage of Float Shorted Over Time Remove Ads Apellis Pharmaceuticals Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 3/15/202519,310,000 shares $476.18 million -7.3%16.7%11 $24.66 2/28/202520,820,000 shares $523.62 million +20.1%18.0%10.5 $25.15 2/15/202517,340,000 shares $475.12 million +1.6%15.0%8 $27.40 1/31/202517,060,000 shares $494.91 million -5.4%N/A6.5 $29.01 1/15/202518,040,000 shares $523.70 million -16.0%N/A6 $29.03 12/31/202421,480,000 shares $685.43 million +7.4%N/A6.9 $31.91 12/15/202420,010,000 shares $664.13 million -8.3%N/A6 $33.19 11/30/202421,810,000 shares $740.01 million -5.9%N/A6.7 $33.93 11/15/202423,180,000 shares $608.94 million +11.5%N/A7.7 $26.27 10/31/202420,790,000 shares $566.74 million -1.4%N/A8.7 $27.26 Get the Latest News and Ratings for APLS and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Apellis Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 10/15/202421,090,000 shares $589.47 million +38.2%N/A9.9 $27.95 9/30/202415,260,000 shares $440.10 million -0.1%N/A7.9 $28.84 9/15/202415,280,000 shares $574.83 million -5.5%N/A9.6 $37.62 8/31/202416,170,000 shares $629.01 million -0.6%N/A11.2 $38.90 8/15/202416,270,000 shares $612.08 million +2.2%N/A11.2 $37.62 7/31/202415,920,000 shares $630.43 million +4.9%N/A10.6 $39.60 7/15/202415,170,000 shares $606.80 million +2.4%N/A10.3 $40.00 6/30/202414,810,000 shares $568.11 million +6.6%N/A10.1 $38.36 6/15/202413,900,000 shares $583.80 million +6.0%N/A10.1 $42.00 5/31/202413,120,000 shares $514.96 million +4.2%N/A9.6 $39.25 5/15/202412,590,000 shares $527.77 million +1.6%N/A8.6 $41.92 4/30/202412,390,000 shares $547.51 million +16.1%N/A8.4 $44.19 4/15/202410,670,000 shares $549.51 million +2.2%N/A8 $51.50 3/31/202410,440,000 shares $613.66 million -1.4%N/A7.1 $58.78 3/15/202410,590,000 shares $600.88 million +5.3%N/A6.7 $56.74 2/29/202410,060,000 shares $623.42 million -2.0%N/A5.1 $61.97 2/15/202410,270,000 shares $694.05 million -3.8%N/A4.9 $67.58 1/31/202410,670,000 shares $675.30 million -11.3%N/A5.1 $63.29 1/15/202412,030,000 shares $844.87 million +2.9%N/A5.4 $70.23 12/31/202311,690,000 shares $699.76 million -9.9%N/A5.1 $59.86 12/15/202312,980,000 shares $683.79 million -14.9%N/A5.2 $52.68 11/30/202315,260,000 shares $822.06 million -5.5%N/A6.4 $53.87 11/15/202316,140,000 shares $781.18 million -0.6%N/A6.9 $48.40 10/31/202316,230,000 shares $789.75 million -12.7%N/A5.2 $48.66 10/15/202318,590,000 shares $900.50 million +10.9%N/A4.5 $48.44 9/30/202316,770,000 shares $637.93 million +23.2%N/A3.3 $38.04 9/15/202313,610,000 shares $604.83 million +10.6%N/A2.9 $44.44 8/31/202312,310,000 shares $519.61 million -10.5%N/A2.7 $42.21 8/15/202313,750,000 shares $449.90 million +43.2%N/A3.1 $32.72 7/31/20239,600,000 shares $247.20 million +1.3%N/A2.6 $25.75The Dirty Secret About Gold Mining Stocks... (Ad)Here's something most gold analysts won't tell you: 90% of gold mining companies actually destroy shareholder value over time. Even as gold prices rise.Right now, I've found 4 miners showing the exact same pattern as previous 100-baggers. 7/15/20239,480,000 shares $801.06 million -1.2%N/A3.5 $84.50 6/30/20239,590,000 shares $873.65 million -16.3%N/A6 $91.10 6/15/202311,460,000 shares $1.03 billion +0.9%N/A6.7 $89.60 5/31/202311,360,000 shares $975.26 million +3.3%N/A7 $85.85 5/15/202311,000,000 shares $969.21 million +7.0%N/A5.6 $88.11 4/30/202310,280,000 shares $857.66 million -16.6%N/A5.4 $83.43 4/15/202312,330,000 shares $998.11 million +0.4%N/A6.7 $80.95 3/31/202312,280,000 shares $809.99 million +1.1%N/A7.1 $65.96 3/15/202312,150,000 shares $796.19 million +13.1%N/A7.6 $65.53 2/28/202310,740,000 shares $703.26 million +18.5%N/A7.4 $65.48 2/15/20239,060,000 shares $479.82 million -0.6%N/A6.5 $52.96 1/31/20239,110,000 shares $480.37 million -5.0%N/A6.9 $52.73 1/15/20239,590,000 shares $504.05 million +4.6%N/A7.4 $52.56 12/30/20229,170,000 shares $474.18 million -8.8%N/A7.1 $51.71 12/15/202210,050,000 shares $526.72 million +1.9%N/A6.9 $52.41 11/30/20229,860,000 shares $492.31 million -5.1%N/A6.6 $49.93 11/15/202210,390,000 shares $484.28 million +6.8%N/A6.3 $46.61 10/31/20229,730,000 shares $588.57 million +10.8%N/A6.6 $60.49 10/15/20228,780,000 shares $499.93 million -10.6%N/A6.4 $56.94 9/30/20229,820,000 shares $670.71 million +7.9%N/A6.8 $68.30 9/15/20229,100,000 shares $589.23 million +8.6%N/A6.9 $64.75 8/31/20228,380,000 shares $507.07 million +4.9%N/A6.5 $60.51 8/15/20227,990,000 shares $548.43 million -18.8%N/A7.4 $68.64 7/31/20229,840,000 shares $553.80 million +5.0%N/A8.8 $56.28 7/15/20229,370,000 shares $431.68 million -4.4%N/A8.8 $46.07 6/30/20229,800,000 shares $443.16 million +7.1%N/A9.9 $45.22 6/15/20229,150,000 shares $376.71 million +2.0%N/A8.1 $41.17 5/31/20228,970,000 shares $371.81 million -2.0%N/A7.5 $41.45 5/15/20229,150,000 shares $360.97 million +3.7%N/A7.5 $39.45 4/30/20228,820,000 shares $383.93 million +12.4%N/A7.7 $43.53 4/15/20227,850,000 shares $414.56 million +7.7%N/A6.8 $52.81 3/31/20227,290,000 shares $370.40 million +14.1%N/A6.3 $50.81 3/15/20226,390,000 shares $255.92 million -7.0%8.0%6.8 $40.05 2/28/20226,870,000 shares $292.18 million -1.3%8.5%8.1 $42.53 2/15/20226,960,000 shares $327.61 million -4.7%8.8%8.2 $47.07 1/31/20227,300,000 shares $293.97 million +17.0%9.3%6.8 $40.27 1/15/20226,240,000 shares $251.85 million -6.7%7.9%5.9 $40.36 12/31/20216,690,000 shares $316.30 million -7.3%8.5%6.5 $47.28 12/15/20217,220,000 shares $320.06 million +9.1%9.2%6.3 $44.33 11/30/20216,620,000 shares $278.57 million +12.4%8.6%3.7 $42.08 11/15/20215,890,000 shares $247.85 million -1.0%7.6%3.2 $42.08 10/29/20215,950,000 shares $182.90 million +4.0%8.6%3.6 $30.74 10/15/20215,720,000 shares $198.08 million -10.2%8.3%3.6 $34.63 9/30/20216,370,000 shares $209.96 million +11.4%9.2%4 $32.96 9/15/20215,720,000 shares $194.02 million +10.6%8.3%3.7 $33.92 8/31/20215,170,000 shares $340.44 million +2.4%7.6%5.8 $65.85 8/13/20215,050,000 shares $290.17 million +2.9%7.5%6.4 $57.46 7/30/20214,910,000 shares $314.19 million -21.2%7.9%5.6 $63.99 7/15/20216,230,000 shares $390.18 million +4.9%10.0%7.1 $62.63 6/30/20215,940,000 shares $375.41 million -0.5%9.5%7 $63.20The Dirty Secret About Gold Mining Stocks... (Ad)Here's something most gold analysts won't tell you: 90% of gold mining companies actually destroy shareholder value over time. Even as gold prices rise.Right now, I've found 4 miners showing the exact same pattern as previous 100-baggers. 6/15/20215,970,000 shares $362.08 million +6.4%9.6%7.7 $60.65 5/28/20215,610,000 shares $315.73 million -18.7%9.0%7.2 $56.28 5/14/20216,900,000 shares $314.92 million -10.6%11.0%8.9 $45.64 4/30/20217,720,000 shares $372.41 million -4.0%N/A12.1 $48.24 4/15/20218,040,000 shares $357.62 million +4.6%N/A12.4 $44.48 3/31/20217,690,000 shares $323.36 million +9.2%N/A11.7 $42.05 3/15/20217,040,000 shares $328.49 million -13.2%N/A10.7 $46.66 2/26/20218,110,000 shares $365.36 million +4.7%12.8%11.8 $45.05 2/12/20217,750,000 shares $366.73 million +1.2%12.4%11 $47.32 1/29/20217,660,000 shares $343.93 million -14.3%12.4%10.6 $44.90 1/15/20218,940,000 shares $479.18 million -1.1%15.1%12.5 $53.60 12/31/20209,040,000 shares $516.46 million +7.1%15.3%13.4 $57.13 12/15/20208,440,000 shares $439.30 million -6.6%14.3%12.3 $52.05 11/30/20209,040,000 shares $426.87 million -9.1%15.3%14.6 $47.22 11/15/20209,940,000 shares $384.98 million -2.5%16.8%16.7 $38.73 10/30/202010,190,000 shares $331.79 million -4.2%17.2%18.1 $32.56 10/15/202010,640,000 shares $376.87 million -2.4%18.0%18.6 $35.42 9/30/202010,900,000 shares $328.85 million +3.8%18.5%16.8 $30.17 9/15/202010,500,000 shares $327.60 million +1.9%17.8%15.5 $31.20 8/31/202010,300,000 shares $317.55 million +0.9%17.5%14 $30.83 8/14/202010,210,000 shares $289.76 million +0.7%17.3%13 $28.38 7/31/202010,140,000 shares $262.52 million +0.8%17.2%12 $25.89 7/15/202010,060,000 shares $321.01 million +4.4%17.1%10.9 $31.91 6/30/20209,640,000 shares $314.84 million +10.2%16.4%10.1 $32.66 6/15/20208,750,000 shares $285.16 million +7.2%14.9%9.1 $32.59 5/29/20208,160,000 shares $277.93 million +11.6%13.9%7.8 $34.06 5/15/20207,310,000 shares $226.61 million +20.2%12.4%6.9 $31.00 4/30/20206,080,000 shares $208.36 million +7.8%10.5%5.9 $34.27 4/15/20205,640,000 shares $180.37 million -1.2%9.7%5.9 $31.98 3/31/20205,710,000 shares $210.53 million -2.0%9.9%3.8 $36.87 APLS Short Interest - Frequently Asked Questions What is Apellis Pharmaceuticals' current short interest? Short interest is the volume of Apellis Pharmaceuticals shares that have been sold short but have not yet been covered or closed out. As of March 15th, traders have sold 19,310,000 shares of APLS short. 16.66% of Apellis Pharmaceuticals' shares are currently sold short. Learn More on Apellis Pharmaceuticals' current short interest. What is a good short interest ratio for Apellis Pharmaceuticals? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. APLS shares currently have a short interest ratio of 11.0. Learn More on Apellis Pharmaceuticals's short interest ratio. Which institutional investors are shorting Apellis Pharmaceuticals? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Apellis Pharmaceuticals: GTS Securities LLC, Wolverine Trading LLC, Jefferies Financial Group Inc., Group One Trading LLC, D. E. Shaw & Co. Inc., Caption Management LLC, Citadel Advisors LLC, Jane Street Group LLC, Tudor Investment Corp ET AL, Boothbay Fund Management LLC, Susquehanna International Group LLP, Concourse Financial Group Securities Inc., Walleye Trading LLC, Walleye Capital LLC, and SG Americas Securities LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. What is a good short interest percentage for Apellis Pharmaceuticals? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 16.66% of Apellis Pharmaceuticals' floating shares are currently sold short. Is Apellis Pharmaceuticals' short interest increasing or decreasing? Apellis Pharmaceuticals saw a drop in short interest in the month of March. As of March 15th, there was short interest totaling 19,310,000 shares, a drop of 7.3% from the previous total of 20,820,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Apellis Pharmaceuticals' short interest compare to its competitors? 16.66% of Apellis Pharmaceuticals' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Apellis Pharmaceuticals: Viatris Inc. (3.91%), Dr. Reddy's Laboratories Limited (1.97%), Ascendis Pharma A/S (12.03%), Sarepta Therapeutics, Inc. (5.50%), Vaxcyte, Inc. (10.44%), Qiagen (1.72%), Roivant Sciences Ltd. (11.87%), Revolution Medicines, Inc. (10.76%), Lantheus Holdings, Inc. (9.73%), Legend Biotech Co. (6.24%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Invesco QQQ ($26.28 billion), iShares 20+ Year Treasury Bond ETF ($9.53 billion), MicroStrategy Incorporated ($8.50 billion), Apollo Global Management, Inc. ($4.86 billion), Super Micro Computer, Inc. ($4.85 billion), Charter Communications, Inc. ($4.28 billion), Capital One Financial Co. ($4.08 billion), AppLovin Co. ($3.82 billion), Canadian Natural Resources Limited ($3.78 billion), and Schlumberger Limited ($2.87 billion). View all of the most shorted stocks. What does it mean to sell short Apellis Pharmaceuticals stock? Short selling APLS is an investing strategy that aims to generate trading profit from Apellis Pharmaceuticals as its price is falling. APLS shares are trading down $0.01 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Apellis Pharmaceuticals? A short squeeze for Apellis Pharmaceuticals occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of APLS, which in turn drives the price of the stock up even further. How often is Apellis Pharmaceuticals' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including APLS, twice per month. The most recent reporting period available is March, 15 2025. More Short Interest Resources from MarketBeat Related Companies VTRS Short Interest Data RDY Short Interest Data ASND Short Interest Data SRPT Short Interest Data PCVX Short Interest Data QGEN Short Interest Data ROIV Short Interest Data RVMD Short Interest Data LNTH Short Interest Data LEGN Short Interest Data Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:APLS) was last updated on 3/30/2025 by MarketBeat.com Staff From Our PartnersA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredThe Dirty Secret About Gold Mining Stocks...Here's something most gold analysts won't tell you: 90% of gold mining companies actually destroy sharehold...Golden Portfolio | SponsoredPartner with Elon Musk on Project Colossus… Before May 1stEven though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks...Brownstone Research | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | SponsoredElon Musk is helping print “new gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredElon’s ‘Strike Squad’ sends these 9 stocks soaring?Elon Musk's DOGE 'strike squad' just revealed it's speeding up the rollout of a radical technology across the ...Altimetry | SponsoredDoomed: These 50 Stocks Will Die Under Trump’s MAGA policies.Remember Kodak? Sears? Circuit City? They all failed to adapt to the changing times. Now, history is abo...Banyan Hill Publishing | SponsoredTrump… a socialist? Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Apellis Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Apellis Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
